KR20230004604A - 암 치료를 위한 클로스트리듐 부티리쿰을 포함하는 조성물 및 방법 - Google Patents

암 치료를 위한 클로스트리듐 부티리쿰을 포함하는 조성물 및 방법 Download PDF

Info

Publication number
KR20230004604A
KR20230004604A KR1020227039551A KR20227039551A KR20230004604A KR 20230004604 A KR20230004604 A KR 20230004604A KR 1020227039551 A KR1020227039551 A KR 1020227039551A KR 20227039551 A KR20227039551 A KR 20227039551A KR 20230004604 A KR20230004604 A KR 20230004604A
Authority
KR
South Korea
Prior art keywords
dose
cancer
clostridium butyricum
cfu
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039551A
Other languages
English (en)
Korean (ko)
Inventor
피터 피 리
수만타 쿠마르 팔
Original Assignee
시티 오브 호프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시티 오브 호프 filed Critical 시티 오브 호프
Publication of KR20230004604A publication Critical patent/KR20230004604A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227039551A 2020-04-21 2021-04-20 암 치료를 위한 클로스트리듐 부티리쿰을 포함하는 조성물 및 방법 Pending KR20230004604A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013141P 2020-04-21 2020-04-21
US63/013,141 2020-04-21
PCT/US2021/028251 WO2021216618A1 (en) 2020-04-21 2021-04-20 Compositions and methods comprising clostridium butyricum for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20230004604A true KR20230004604A (ko) 2023-01-06

Family

ID=78270016

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039551A Pending KR20230004604A (ko) 2020-04-21 2021-04-20 암 치료를 위한 클로스트리듐 부티리쿰을 포함하는 조성물 및 방법

Country Status (8)

Country Link
US (1) US12589123B2 (enExample)
EP (1) EP4138869A4 (enExample)
JP (2) JP7813240B2 (enExample)
KR (1) KR20230004604A (enExample)
CN (1) CN116390737A (enExample)
AU (1) AU2021261290A1 (enExample)
CA (1) CA3180564A1 (enExample)
WO (1) WO2021216618A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415900A1 (en) * 2021-10-20 2024-12-19 City Of Hope Clostridium butyricum compositions and methods of using the same
CN115671142A (zh) * 2022-11-15 2023-02-03 中山大学附属第六医院 丁酸梭菌在结直肠癌辅助治疗上的应用
CN116650534B (zh) * 2023-03-10 2026-07-28 中南大学 丁酸梭菌及其细菌外囊泡在制备治疗多发性骨髓瘤或复发难治多发性骨髓瘤制剂中的应用
CN121152637A (zh) * 2023-05-23 2025-12-16 日本米雅利桑制药株式会社 癌治疗用组合药物
CN116687979B (zh) * 2023-06-28 2025-06-20 中国人民解放军陆军军医大学 肠道微生物在稳定肠道谷氨酰胺以及在制备治疗癌症的药物中的应用
CN120131715A (zh) * 2025-03-14 2025-06-13 中山大学孙逸仙纪念医院 膀胱灌注丁酸梭菌免疫制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6153219A (ja) 1984-08-23 1986-03-17 Tadashi Arai 抗腫瘍剤
JP2009269836A (ja) 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
EP3518946A4 (en) * 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
WO2019165285A1 (en) * 2018-02-23 2019-08-29 Crestovo Holdings Llc Microbiome related immunotherapies
WO2019178542A1 (en) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
CN109771445B (zh) 2019-03-20 2022-08-05 青岛东海药业有限公司 酪酸梭菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用

Also Published As

Publication number Publication date
JP2026031928A (ja) 2026-02-25
CN116390737A (zh) 2023-07-04
US12589123B2 (en) 2026-03-31
EP4138869A4 (en) 2024-05-15
JP2023522716A (ja) 2023-05-31
US20230149479A1 (en) 2023-05-18
EP4138869A1 (en) 2023-03-01
AU2021261290A1 (en) 2022-11-03
JP7813240B2 (ja) 2026-02-12
WO2021216618A1 (en) 2021-10-28
CA3180564A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US12589123B2 (en) Compositions and methods comprising clostridium butyricum for the treatment of cancer
US12235270B2 (en) Depleting tumor-specific tregs
JP2022130413A (ja) Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
CN110582291A (zh) 抗pd1/pd-l1/pd-l2抗体的反应性标志物和功效改善用调节剂
KR20220116438A (ko) 암 치료를 위한 미생물총 및 대사산물의 힘 활용
US20260015413A1 (en) Compositions and methods for targeting activin signaling to treat cancer
JP7750871B2 (ja) 治療用細菌組成物
WO2025072639A1 (en) Methods of treating cancer resistant to immune checkpoint therapy and compositions useful for the same
US20220080001A1 (en) Methods and compositions for treating immune checkpoint inhibitor associated colitis
US20230002502A1 (en) Methods and products for reducing side effects associated with use of immune agonist antibodies
WO2026104810A1 (en) Isolated bacteria or culture supernatants thereof for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000